Operating margin is thin at 4.94%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (FY)
$190M
Net Income (TTM)
$96M
▲ +111.9% YoY
Op. Margin
4.94%
ROIC
14.43%
▲ +66.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$105M
▲ +167.4% YoY
Op. Cash Flow (TTM)
$106M
▲ +167.7% YoY
Net Debt
-$201M
Net Cash Position
Cash & Equiv.
$256M
Continue Research
SourceComputed from the 10-Q filed 30 Apr 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 3 Sept 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong? Check it in SLNO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SLNO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.